CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹61 Cr | ₹-31 Cr | ₹82 Cr | ₹184 Cr | ₹622 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹61 Cr |
| Mar2025 | ₹-31 Cr |
| Mar2024 | ₹82 Cr |
| Mar2023 | ₹184 Cr |
| Mar2022 | ₹622 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹61 Cr | Positive | |
| Mar2025 | ₹-31 Cr | Negative | |
| Mar2024 | ₹82 Cr | -55.36 | |
| Mar2023 | ₹184 Cr | -70.48 | |
| Mar2022 | ₹622 Cr | - | |
Compare Total Non-Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹113,972.5 Cr | -2.1% | -1.8% | -6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹465,711.0 Cr | -0.8% | 3.5% | 14.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,376.0 Cr | -1% | 7.3% | 7.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,655.0 Cr | -0.9% | 10.1% | 44.6% | Stock Analytics | |
| MANKIND PHARMA | ₹103,472.0 Cr | -2.4% | 1.2% | -3.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,204.7 Cr | -5.8% | -13.2% | -7.7% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -2.1% |
-1.8% |
-6% |
| SENSEX | -2.7% |
-0.2% |
-8% |
You may also like the below Video Courses